# A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

> **NCT01602549** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 58 (actual)

## Conditions studied

- Gastroparesis

## Interventions

- **DRUG:** GSK962040 (25 mg tablet)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01602549
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602549, "A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01602549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*